High stromal PDGFRb expression as a novel biomarker identifying ductal carcinoma in situ (DCIS) patients who are refractory to standard whole‐breast adjuvant radiotherapy. This evidence concerns the gene PDGFRB and ductal breast carcinoma in situ.